The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•30 March 2026•

1 min read

Seer, Inc. Wins Patent Dispute Against Bruker Subsidiaries

Key Facts

1The Patent Trial and Appeal Board upheld the validity of 23 claims of Seer's U.S. Patent No. 11,435,360.

2The patent relates to nano and microparticle protein enrichment technology, which is central to Seer's Proteograph Product Suite.

Version History

1 additional source confirmed this story

The Patent Trial and Appeal Board (PTAB) has ruled in favor of Seer, Inc., upholding the validity of a critical patent. The ruling confirms 23 claims of U.S. Patent No. 11,435,360, which were challenged by subsidiaries of Bruker Corporation. This patent covers essential nano and microparticle protein enrichment technology used in Seer's Proteograph Product Suite. By successfully defending its intellectual property, Seer maintains a significant competitive advantage in the proteomics market. The decision removes a major legal uncertainty that had been looming over the company's core technology. Market analysts view this outcome as a positive development for Seer's long-term valuation and market position.